SQLite Web: event_store.db

Could not fetch row with primary-key 52189.

Update row 63017 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:d6411c6759ca3324","evidence_event_ids":["evt_83f4af2f055a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","company":"Spyre Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_60c8520058b1e6ef","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","content_type":"text/plain","enriched_at":"2026-04-17T08:09:56.539248+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"Document","final_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt","source_event_id":"evt_83f4af2f055a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"c9f5edd18087d4ab","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-16","2026-04-14","2026-04-17","2026-02-27","2026-02-19"],"entities":[{"asset_class":"equity","name":"Spyre Therapeutics, Inc.","relevance":"high","symbol":"SYRE","type":"issuer"},{"asset_class":"other","name":"LifeSci Capital","relevance":"medium","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Passive Bookrunner","relevance":"low","symbol":"","type":"underwriting role"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal beyond the fact that this filing was discovered; no prior filing state/details are included to compare.","No underwriting discounts/commissions amounts are provided in the extracted text (only referenced).","No total gross proceeds/net proceeds are stated in the provided text excerpt.","No use of proceeds or risk factor specifics are included in the excerpt beyond general references."],"key_facts":["Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) for Registration Statement No. 333-293600.","Offering size: 6,500,000 shares of common stock, par value $0.0001 per share.","Public offering price: $62.00 per share.","Nasdaq Global Select Market symbol: SYRE.","Last reported sale price on April 14, 2026: $64.01 per share.","Underwriters have an option to purchase up to an additional 975,000 shares within 30 days at the public offering price, less underwriting discounts and commissions.","Expected delivery of shares: on or about April 16, 2026.","The prospectus supplement relates to an effective shelf registration statement on Form S-3 (File No. 333-293600) filed February 19, 2026 and effective February 27, 2026."],"numeric_claims":[{"label":"shares_offered","value":"6,500,000"},{"label":"public_offering_price_per_share_usd","value":"62.00"},{"label":"last_reported_sale_price_per_share_usd","value":"64.01"},{"label":"additional_option_shares","value":"975,000"},{"label":"option_period_days","value":"30"},{"label":"expected_delivery_date","value":"on or about April 16, 2026"}],"primary_claim":"The company is offering 6,500,000 shares of common stock at a public offering price of $62.00 per share under a Form 424B5 prospectus supplement.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Spyre Therapeutics, Inc. filed a prospectus supplement on Form 424B5 for an underwritten public offering of 6,500,000 shares of its common stock at $62.00 per share.","topics":["SEC filing","public offering","common stock","underwriting","shelf registration","Nasdaq","prospectus supplement"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 Spyre Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"SYRE","tickers":["SYRE"],"title":"SYRE filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025310.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel